Skip to main content
Journal cover image

Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.

Publication ,  Journal Article
Bergersen, KV; Zheng, Y; Rossetti, M; Ruffin, F; Pickering, H; Parmar, R; Sunga, G; Chan, LC; Gjertson, D; Fowler, VG; Yeaman, MR; Reed, EF ...
Published in: BMC Infect Dis
February 18, 2025

BACKGROUND: Staphylococcus aureus bacteremia (SAB) is a prevalent life-threatening infection often caused by methicillin-resistant S. aureus (MRSA). Up to 30% of SAB patients fail to clear infection even with gold-standard anti-MRSA antibiotics. This phenomenon is termed antibiotic-persistent MRSA bacteremia (APMB). The mechanisms driving APMB are complex and involve host phenotypes significantly impacting the immune response. Thus, defining early immune signatures and clinical phenotypes that differentiate APMB from antibiotic resolving (AR)MB could aid therapeutic success. METHODS: We assessed 38 circulating cytokines and chemokines using affinity proteomics in 74 matched pairs of vancomycin-treated SAB cases identified as ARMB or APMB after 5 days of blood culture. RESULTS: Unsupervised hierarchical clustering segregated APMB from ARMB based on differential levels of IL-10, IL-12p40, IL-13, CCL4, and TGFα. Additionally, CXCL1, CCL22 and IL-17A significantly differed between APMB and ARMB when correlated with diabetes, dialysis, metastatic infection, or cardiac vegetation. Combining immune signatures with these relevant clinical phenotypes sharply increased accuracy of discriminating APMB outcome to 79.1% via logistic regression modeling. Finally, classification-regression tree analysis revealed explicit analyte thresholds associated with APMB outcome at presentation especially in patients with metastatic infection. CONCLUSIONS: Collectively, this study identifies previously unrecognized cytokine and chemokine signatures that distinguish APMB and ARMB at presentation and in the context of host clinical characteristics associated with increased disease severity. Validation of a biomarker signature that accurately predicts outcomes could guide early therapeutic strategies and interventions to reduce risks of persistent SAB that are associated with worsened morbidity and mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMC Infect Dis

DOI

EISSN

1471-2334

Publication Date

February 18, 2025

Volume

25

Issue

1

Start / End Page

231

Location

England

Related Subject Headings

  • Vancomycin
  • Staphylococcal Infections
  • Proteomics
  • Phenotype
  • Middle Aged
  • Microbiology
  • Methicillin-Resistant Staphylococcus aureus
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bergersen, K. V., Zheng, Y., Rossetti, M., Ruffin, F., Pickering, H., Parmar, R., … MRSA Systems Immunobiology Group. (2025). Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia. BMC Infect Dis, 25(1), 231. https://doi.org/10.1186/s12879-025-10620-3
Bergersen, Kristina V., Ying Zheng, Maura Rossetti, Felicia Ruffin, Harry Pickering, Rajesh Parmar, Gemalene Sunga, et al. “Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC Infect Dis 25, no. 1 (February 18, 2025): 231. https://doi.org/10.1186/s12879-025-10620-3.
Bergersen KV, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R, et al. Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia. BMC Infect Dis. 2025 Feb 18;25(1):231.
Bergersen, Kristina V., et al. “Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC Infect Dis, vol. 25, no. 1, Feb. 2025, p. 231. Pubmed, doi:10.1186/s12879-025-10620-3.
Bergersen KV, Zheng Y, Rossetti M, Ruffin F, Pickering H, Parmar R, Sunga G, Chan LC, Gjertson D, Fowler VG, Yeaman MR, Reed EF, MRSA Systems Immunobiology Group. Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia. BMC Infect Dis. 2025 Feb 18;25(1):231.
Journal cover image

Published In

BMC Infect Dis

DOI

EISSN

1471-2334

Publication Date

February 18, 2025

Volume

25

Issue

1

Start / End Page

231

Location

England

Related Subject Headings

  • Vancomycin
  • Staphylococcal Infections
  • Proteomics
  • Phenotype
  • Middle Aged
  • Microbiology
  • Methicillin-Resistant Staphylococcus aureus
  • Male
  • Humans
  • Female